305 related articles for article (PubMed ID: 23986353)
1. Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit/hyperactivity disorder participating in psychopharmacology clinical trials.
Khan A; Faucett J; Morrison S; Brown WA
JAMA Psychiatry; 2013 Oct; 70(10):1091-9. PubMed ID: 23986353
[TBL] [Abstract][Full Text] [Related]
2. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports.
Alper K; Schwartz KA; Kolts RL; Khan A
Biol Psychiatry; 2007 Aug; 62(4):345-54. PubMed ID: 17223086
[TBL] [Abstract][Full Text] [Related]
3. Psychiatric diagnosis and clinical trial completion rates: analysis of the FDA SBA reports.
Khan A; Schwartz K; Redding N; Kolts RL; Brown WA
Neuropsychopharmacology; 2007 Nov; 32(11):2422-30. PubMed ID: 17314915
[TBL] [Abstract][Full Text] [Related]
4. Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials.
Khan A; Schwartz K; Stern C; Redding N; Kolts RL; Brown WA; Robinson DS
J Clin Psychiatry; 2007 Dec; 68(12):1828-33. PubMed ID: 18162012
[TBL] [Abstract][Full Text] [Related]
5. Mortality during US FDA clinical trials in patients with diabetes, hypertension, depression and schizophrenia.
Khan A; Fahl Mar K; Gokul S; Brown WA
World J Biol Psychiatry; 2020 Jan; 21(1):64-71. PubMed ID: 30246595
[No Abstract] [Full Text] [Related]
6. [Deaths in a Tunisian psychiatric hospital: an eleven-year retrospective study].
Zgueb Y; Jomli R; Ouertani A; Hechmi S; Ouanes S; Nacef F; Banaser A
Encephale; 2014 Oct; 40(5):416-22. PubMed ID: 25132014
[TBL] [Abstract][Full Text] [Related]
7. Suicide rates in short-term randomized controlled trials of newer antidepressants.
Hammad TA; Laughren TP; Racoosin JA
J Clin Psychopharmacol; 2006 Apr; 26(2):203-7. PubMed ID: 16633153
[TBL] [Abstract][Full Text] [Related]
8. ECNP consensus meeting. Bipolar depression. Nice, March 2007.
Goodwin GM; Anderson I; Arango C; Bowden CL; Henry C; Mitchell PB; Nolen WA; Vieta E; Wittchen HU
Eur Neuropsychopharmacol; 2008 Jul; 18(7):535-49. PubMed ID: 18501566
[TBL] [Abstract][Full Text] [Related]
9. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
10. Suicide risk analysis among patients assigned to psychotropics and placebo.
Khan A; Kolts RL; Brodhead AE; Krishnan KR; Brown WA
Psychopharmacol Bull; 2006; 39(1):6-14. PubMed ID: 17065970
[TBL] [Abstract][Full Text] [Related]
11. [Review of psychopharmacological treatments in adolescents and adults with autistic disorders].
Baghdadli A; Gonnier V; Aussilloux C
Encephale; 2002; 28(3 Pt 1):248-54. PubMed ID: 12091786
[TBL] [Abstract][Full Text] [Related]
12. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
13. Treatment of depression--newer pharmacotherapies.
Mulrow CD; Williams JW; Trivedi M; Chiquette E; Aguilar C; Cornell JE; Badgett R; Noël PH; Lawrence V; Lee S; Luther M; Ramirez G; Richardson WS; Stamm K
Psychopharmacol Bull; 1998; 34(4):409-795. PubMed ID: 10513454
[TBL] [Abstract][Full Text] [Related]
14. Costs associated with attempted suicide among individuals with bipolar disorder.
Stensland MD; Zhu B; Ascher-Svanum H; Ball DE
J Ment Health Policy Econ; 2010 Jun; 13(2):87-92. PubMed ID: 20919595
[TBL] [Abstract][Full Text] [Related]
15. Magnitude of placebo response and drug-placebo differences across psychiatric disorders.
Khan A; Kolts RL; Rapaport MH; Krishnan KR; Brodhead AE; Browns WA
Psychol Med; 2005 May; 35(5):743-9. PubMed ID: 15918351
[TBL] [Abstract][Full Text] [Related]
16. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of anti-manic agents in children and adults.
Khan A; Faucett J; Emslie GJ; Brown WA
Isr J Psychiatry Relat Sci; 2012; 49(2):122-7. PubMed ID: 22801291
[TBL] [Abstract][Full Text] [Related]
18. Lamotrigine in psychiatric disorders.
Reid JG; Gitlin MJ; Altshuler LL
J Clin Psychiatry; 2013 Jul; 74(7):675-84. PubMed ID: 23945444
[TBL] [Abstract][Full Text] [Related]
19. National trends in psychotropic medication polypharmacy in office-based psychiatry.
Mojtabai R; Olfson M
Arch Gen Psychiatry; 2010 Jan; 67(1):26-36. PubMed ID: 20048220
[TBL] [Abstract][Full Text] [Related]
20. The risk of death among adult participants in trials of antipsychotic drugs in schizophrenia.
Isaac M; Koch A
Eur Neuropsychopharmacol; 2010 Mar; 20(3):139-45. PubMed ID: 20053539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
